摘要
目的:探讨乳腺癌患者有关辅助诊疗、血管生成、炎症趋化及纤维化作用的水平变化及临床意义.方法:选择于2017年3月~2018年3月间在我院治疗的50例乳腺癌患者作为观察组,选取50例同期体检健康者作为对照组,观察比较两组辅助诊疗[包括胸苷激酶1(TK1)、糖类抗原153(CA153)、癌胚抗原(CEA)]、血管生成[包括血管内皮生长因子-C(VEGF-C)、血管内皮生长因子受体-3(VEGFR-3)]、炎症趋化[包括趋化因子18(CCL18)、趋化因子20(CCL20)、趋化因子受体3(CXCR3)]及纤维化作用[包括可溶性细胞间粘附分子-1(sICAM-1)、缔结组织生长因子(CTGF)]相关指标的表达水平.结果:观察组TK1[(6.74±2.34)pmol/L]、CA153[(52.48±19.86)U/mL]、CEA[(6.02±2.88)ng/mL]、VEGF-C[(317.07±21.63)ng/L]、VEGFR-3[(972.78±104.26)ng/L]、CCL18[(297.15± 95.38)pg/mL]、CCL20[(123.32±52.77)pg/mL]、CXCR3[(177.48±52.41)ng/L]、sICAM-1[(1415.81±437.46)ng/mL]及CTGF[(10.38±3.16)ng/mL]水平均显著高于对照组TK1[(0.36±0.06)pmol/L]、CA153[(11.41±3.68)U/mL]、CEA[(1.94±0.72)ng/mL]、VEGF-C[(60.90±14.56)ng/L]、VEGFR-3[(117.25±22.37)ng/L]、CCL18[(124.10± 19.44)pg/mL]、CCL20[(65.85±16.99)pg/mL]、CXCR3[(88.16±30.52)ng/L]、sICAM-1[(285.60±44.08)ng/mL]及CTGF[(2.31±0.32)ng/mL],差异有统计学意义.结论:乳腺癌患者容易新生成肿瘤血管,引发炎症,出现纤维化,应加强相关指标的检测,为早期诊断及治疗乳腺癌提供依据.
Objective To investigate the changes and clinical significance of adjuvant diagnosis and treatment, angiogenesis, inflammatory chemotaxis and fibrosis in patients with breast cancer. Methods Fifty patients with breast cancer treated in our hospital from March 2017 to March 2018 were selected as the observation group and 50 healthy persons as the control group. The expression levels of the indexes related to adjuvant diagnosis and treatment [ including thymidine kinase 1(TK1), carbohydrate antigen 153(CA153) and carcinoembryonic antigen (CEA)], angiogenesis [ including vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor receptor-3(VEGFR-3)], inflammatory chemotaxis [ including chemokine 18(CCL18), chemokine 20(CCL20), chemokine receptor 3(CXCR3)] and fibrosis〔 including soluble intercellular adhesion molecule-1 (sICAM-1) and tissue growth factor (CTGF)] between the two groups were observed and compared. Results The level of TK1 [(6.74 ± 2.34) pmoVL ], CA153[(52.48 ± 19.86) U/mL ], CEA[(6.02 ± 2.88) ng/mL ], VEGF-C[(317.07 ± 21.63) ng/L ], VEGFR-3[(972.78 ±104.26) ng/L ],CCL18[(297.15 ± 95.38) pg/mL ], CCL20[(123.32 ± 52.77) pg/mL ], CXCR3[(177.48 ± 52.41) ng/L],sICAM- 1 [(1415.81 ± 437.46) ng/mL ] and CTGF[(10.38 ±3.16) ng/mL ] of the observation group was significantly higher than that of the control grou讥 TK1 [(0.36 土 0.06) pmol/L ], CA153 [(11.41 ± 3.68) U/mL ], CEA[(1,94 ± 0.72) ng/mL ], VEGF-C [(60.90 ± 14.56) ng/L ], VEGFR-3 [(117.25 ± 22.37) ng/L], CCL18[(124.10 ± 19.44) pg/mL L CCL20[(65.85 ± 16.99) pg/ mL ], CXCR3 [(88.16 ± 30.52) ng/L ], sICAM-1 [(285.60 ± 44.08) ng/mL ] and CTGF[(2.31 ± 0.32) ng/mL ]. The difference was statistically significant. Conclusions Patients with breast cancer are prone to neovascularization, inflammation and fibrosis. It is necessary to strengthen the detection of relevant indicators to provide evidence for early diagnosis and treatment of breast cancer.
作者
叶绍兵
王家瑞
刘高
谢敏
Ye Shao-bing;Wang Jia-rui;Liu Gao;Xie Min(General Surgery Department,Chongqing Kaizhou District People's Hospital,Chongqing 405400,China;Department of Maternal and Child Health,Wenfeng Street Health Service Center,Kaizhou District,Chongqing 405400,China)
出处
《湖南师范大学学报（医学版）》
2019年第5期25-28,共4页
Journal of Hunan Normal University(Medical Sciences)
基金
重庆市科委项目（Cste2015jcsf10012）
关键词
乳腺癌
辅助诊疗
血管生成
炎症趋化
纤维化
breast cancer
auxiliary diagnosis and treatment
angiogenesis
inflammation chemotactic
fib
